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1. Introduction 
1.1 Management options for clinical stage I non-seminomatous germ cell tumor of the 
testis 
1.1.1 Introduction to clinical stage I disease 
About 5-7/100,000 men are diagnosed with testis cancer annually. A large proportion of 
these are pathologically classified as non-seminomatous germ cell tumor (NSGCT). The 
majority of NSGCT patients present with clinical stage (CS) I disease, which is characterized 
by a germ cell tumor confined to the testis, a negative metastatic work-up which includes a 
chest X-ray (CXR), computed tomography scan of the abdomen and pelvis (CT A&P), and 
negative serum tumor markers (STM) post-orchiectomy. Patients who present with CS I 
testis cancer have a 30 percent chance of harboring occult metastatic disease post-
orchiectomy, and thus controversy exists as to what represents the best treatment strategy 
following radical orchiectomy. Currently, there are 3 treatment strategies available for 
patients with CS I testis cancer, each one associated with a 99% cure rate: surveillance, 
adjuvant chemotherapy, and primary retroperitoneal lymph node dissection (RPLND). 
1.2 Risk stratification for stage I disease 
The ability to risk classify CSI patients to “high risk” of harboring micrometastatic disease 
and “low risk” of having micrometastatic disease would aid in tailoring therapy. Those 
patients identified as “high risk” could more preferentially be treated with primary RPLND 
or adjuvant chemotherapy, as they would have a greater risk of relapse on surveillance. 
Conversely, “low risk” patients may be managed with surveillance as they would have a 
greater likelihood of being cured with orchiectomy alone and thus overtreated with primary 
RPLND or adjuvant chemotherapy. 
Several key studies have been published identifying pathologic factors predictive of 
metastatic disease in these patients. In 1987, a retrospective MRC trial identified four 
important negative prognostic indicators: presence of embryonal carcinoma, absence of yolk 
sac tumor, vascular invasion of the primary tumor, and lymphatic invasion of the primary 
tumor. (Freedman et al., 1987) These risk factors were then evaluated prospectively, 
revealing the presence of 3 or more risk factors as predictive of recurrence in approximately 
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50% of patients, and the presence of 2 or less risk factors as predictive of micrometastatic 
disease in about 20% of patients. Notably, vascular invasion of the primary tumor was most 
predictive. (Read et al., 1992) More recently, Vergouwe et al. reviewed 23 publications 
assessing predictors of occult metastases. (Vergouwe, Steyerberg, Eijkemans, Albers, & 
Habbema, 2003) Of the 2,587 total patients involved, 759 (29.3%) patients had occult 
metastasis. Pooled univariate odds ratios identified that lymphovascular invasion of the 
primary tumor, embryonal carcinoma component representing >50% of tumor, advanced 
pathologic stage (T2-4 versus T1), and monoclonal antibody MIB-1 staining greater than 70% 
of the tumor as the strongest predictors of occult metastases. Though somewhat variable, 
high risk groups, with the presence of either or both lymphovascular invasion and an 
embryonal dominant primary, carried a recurrence rate of approximately 50%. In patients 
without either pathologic variable, a recurrence rate of less than 20% was observed.  
At best, with current risk classification, 50% of the “high risk” group harbor micrometastatic 
disease and 50% are cured by orchiectomy alone. Thus any therapy beyond orchiectomy for 
the “high risk” group overtreats 50% of patients, who are never destined to relapse. As such, 
risk classification is less than ideal in determining treatment. Future research aims to 
improve the prognostic ability of risk classification. 
1.3 Surveillance for clinical stage I disease 
1.3.1 Clinical outcomes of surveillance 
The primary rationale for surveillance as a therapeutic modality is: 1) it avoids any further 
therapy in the 70% patients who do not harbor micrometastatic disease and who were cured 
by orchiectomy alone, and 2) those 30% of patients that relapse are curable with 
chemotherapy and/or surgery. To achieve a high cure rate, all patients on surveillance must 
be adherent to a strict follow-up schedule to identify those destined to relapse.  
While surveillance avoids therapy in the large proportion of patients who are not destined 
to recur, there remains a burden of therapy for those that do. Some surveillance patients 
relapsing in the retroperitoneum with normal serum tumor markers may be candidates for 
primary RPLND. The remainder will require 3 courses of chemotherapy, and approximately 
a quarter of these will require surgery following chemotherapy. In the single center 
surveillance series of testis cancer patients from Toronto, at a median follow up of 6.3 years, 
104 of 371 (28%) patients relapsed on surveillance. (Kakiashvili, Zuniga, & Jewett, 2009) Of 
the 104 patients that recurred, the burden of therapy included chemotherapy alone in 31, 
surgery alone in 31, and a combination of chemotherapy, surgery and radiation in the 
remaining 42 patients. Similar results were seen in a cohort of 223 patients from British 
Columbia and Oregon, where 26% relapsed on surveillance. (Kollmannsberger et al., 2010) 
No deaths were observed among those who recurred, although 20% of those who relapsed 
(8% of the original cohort) required post-chemotherapy retroperitoneal lymph node 
dissection (PC RPLND) in addition to chemotherapy.  
Despite those recurrences, the overall survival for patients on surveillance equals that of 
primary RPLND or adjuvant chemotherapy. In a pooled analysis of 3424 patients on 
surveillance in series that reported death, a 98.6% disease specific survival was 
demonstrated. (Groll, Warde, & Jewett, 2007)  
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1.3.2 Follow up for surveillance 
While some patients on surveillance will bear the burden of therapy upon relapse, all 
patients on surveillance bear the burden of compliance. Studies indicate that up to a third of 
patients miss at least one clinic visit. (Divrik, Akdogan, Ozen, & Zorlu, 2006; Meinke, Estes, 
& Ernst, 1979) A recent evaluation of compliance of CS I patients at the University of 
Calgary showed extremely poor compliance with scheduled follow up. (Hao et al., 1998) In 
this study, compliance with clinic visits and tumor markers was only 61% during the first 
year and 35% in year 2. Furthermore, compliance with scheduled CT scans was only 25% in 
year 1 and 12% in year 2. The only two deaths in 76 total patients were in individuals who 
were non-compliant with follow up. There is concern that non-compliance may translate 
into a decrease in disease specific survival. (Colls et al., 1999; Gels et al., 1995; Kakehi, 
Kamoto, Kawakita, & Ogawa, 2002; Raghavan et al., 1988) Nevertheless, the true impact of 
non-compliance on survival is unknown. A national surveillance study in New Zealand 
failed to correlate non-compliance with compromise in cure. (Colls, et al., 1999) 
In addition to the risk of poor compliance, some patients on a surveillance protocol will 
experience anxiety due to the possibility of relapse. Although such anxiety is difficult to 
quantify, it is understandable that for some patient personalities, active therapy by way of 
primary RPLND or chemotherapy would be more desirable. 
The burden of compliance involves more than anxiety or clinic attendance. Compliance with 
scheduled imaging studies will result in increased radiation exposure, and this exposure 
carries a slightly increased risk of secondary malignancy in this young population. (Brenner 
& Hall, 2007) Given higher relapse rates in the first 2 years of surveillance, (Groll, et al., 
2007) more intensive follow-up is required in this time period using a combination of 
physical exam, CXR, STM, and CT A&P. In an effort to minimize radiation exposure, a 
randomized trial evaluated CT A&P at 3 and 12 months versus 3, 6, 9, 12, and 24 months 
and found no detection benefit in more frequent imaging. This study involved 414 patients 
with a median follow-up of 40 months, though only 10% of the patients were considered 
high risk based on vascular invasion. (Rustin et al., 2007) A popular follow-up schedule is 
that of the Toronto group, which is of moderate frequency compared to the aforementioned 
schedules, and is outlined in Table 1. 
 Month 2 Month 4 Month 6 Month 8 Month 10 Month 12 
Year 1 STM,CXR
STM,CXR,CT 
A&P 
STM, 
CXR 
STM,CXR,CT 
A&P 
STM, 
CXR 
STM,CXR,CT 
A&P 
Year 2 STM,CXR
STM,CXR,CT 
A&P 
STM, 
CXR 
STM,CXR,CT 
A&P 
STM, 
CXR 
STM,CXR,CT 
A&P 
Year 3  STM,CXR  STM,CXR  STM,CXR 
Year 4   STM,CXR   STM,CXR 
Year 5      STM,CXR 
Table 1. Toronto CS I NSGCT Surveillance Schedule  
In addition to compliance issues, surveillance protocols also affect fertility rates, which 
approach 65% during surveillance, but decreases to 20% for surveillance patients that recur. 
(Herr, Bar-Chama, O'Sullivan, & Sogani, 1998).  
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1.3.3 Summary: Surveillance for clinical stage I disease 
Surveillance offers an equal cure rate to either primary RPLND or adjuvant chemotherapy, 
and does so while avoiding further therapy in 70% of patients. Therefore, it is arguably the 
treatment option of choice in patients without significant pathologic risk factors for occult 
retroperitoneal metastases, who are willing to undergo serial imaging and intense follow-
up. However, patients who choose surveillance must be aware of the importance of 
adherence to their follow-up schedule, and the fact that 30% of patients will require 
chemotherapy at relapse. As a result, patients strongly averse to chemotherapy may not 
wish to choose a surveillance protocol, favoring primary RPLND instead.  
1.4 Adjuvant chemotherapy for clinical stage I disease 
1.4.1 Clinical outcomes of adjuvant chemotherapy 
The rationale for chemotherapy in CS I NSGCT is that it virtually eliminates the risk of 
recurrence, with an incidence rate much lower than that observed with either primary 
RPLND or surveillance. Recurrence rates were reported by the Spanish Germ Cell Group 
involving 231 high risk patients who received two courses of bleomycin, etoposide, and 
cisplatinum (BEP). (Maroto et al., 2005) Two patients (0.9%) relapsed and both are disease 
free after salvage therapy. Long-term follow up extending 10 years has confirmed the low 
relapse rates associated with adjuvant chemotherapy. (Chevreau et al., 2004; Westermann et 
al., 2008) Similarly low recurrence rates have been reported in other series also using 2 
courses of BEP, (Cullen et al., 1996; Oliver, Raja, Ong, & Gallagher, 1992) allowing clinicians 
to draw the conclusion that there is little doubt on the efficacy of chemotherapy in 
preventing recurrence and achieving cure rates similar to surveillance or RPLND strategies 
for CS I NSGCT patients. 
1.4.2 Morbidity of adjuvant chemotherapy 
While the recurrence rates following 2 cycles of adjuvant BEP are impressively low, all 
patients, including the 70% who did not require this additional therapy, are subjected to the 
burden of systemic chemotherapy. Given the young age of most testis cancer patients, a 
lifetime remains to accrue complications secondary to this treatment choice. Specifically, the 
Royal Marsden Hospital reported a 2-fold greater risk of developing cardiovascular disease 
in testis cancer patients treated with chemotherapy and radiation. (Huddart et al., 2003) 
Others have reported that cured patients treated with cisplatin-based chemotherapy have a 
higher prevalence of hypertension and an excessive weight gain compared with patients 
treated with other modalities, and compared to controls. (Sagstuen et al., 2005) A recent 
report evaluated the long-term toxicity of cisplatin-based chemotherapy in 1409 men at a 
median follow-up of 10.7 years. (Brydoy et al., 2009) All chemotherapy groups had 
statistically higher odds of toxicity than men who did not receive chemotherapy, and that 
toxicity most commonly included Raynaud-like phenomena in 39%, paresthesias in the 
hands or feet in 29%, hearing impairment in 21% and tinnitus in 22%. Finally, it is worth 
noting that fertility rates during chemotherapy will drop substantially, recovering to 
approximately an 85% conception rate for couples desiring children, with a mean of 3 years 
of follow up. (Huyghe et al., 2004)  
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Bearing these concerning morbidity rates in mind, efforts have been made to decrease the 
toxicity of chemotherapy regimens by decreasing dose rates. Investigators have attempted to 
decrease the exposure to chemotherapy by treating clinical stage I patients with a single cycle 
of BEP. The Swiss Group for Clinical Cancer Research reported outcomes of high risk stage I 
patients receiving a single course of BEP in the adjuvant setting. (Westermann, et al., 2008) 
Data from 40 of the 44 patients were analyzed. Thirty-five showed no evidence of disease 
during a median follow up of 99 months. One patient developed pulmonary metastases after 
13 months and died of pneumonia. Two patients developed contralateral testis cancer, 
subsequently received three cycles of BEP, and were relapse free for 4 and 92 months, 
respectively, thereafter. Two final patients were free of disease at 10 and 31 months when lost 
to follow-up. Also utilizing one course of BEP, the German Testicular Cancer Study Group has 
reported a 2-year disease free survival of 99.5% after a median follow up of 4.7 years, with just 
2 recurrences observed in the intention-to-treat population. (Albers et al., 2008) 
1.4.3 Follow up for adjuvant chemotherapy 
During chemotherapy, serum markers are monitored prior to each cycle. Upon completion 
of 2 cycles of BEP, patient follow-up need be tailored based upon individual patient 
outcomes, and will include periodic physical examination, serum markers, and imaging of 
the chest, abdomen, and pelvis. (L. Wood et al., 2010) 
1.4.4 Summary: Adjuvant chemotherapy for clinical stage I disease 
To summarize chemotherapy as a treatment option, its greatest advantage lies in its 
recurrence rate of less than 2%. However, it subjects all patients, including the 70% never 
destined to recur, to the short and long term complications of systemic chemotherapy. While 
recent data suggest that one cycle of BEP may be adequate to achieve acceptably low 
recurrence rates, the standard of care continues to be two cycles of BEP, and the attendant 
morbidities of this therapeutic choice must be borne in mind. 
1.5 Primary RPLND for clinical stage I disease 
1.5.1 Clinical outcomes of primary RPLND – pathologic stage I disease 
Testis cancer is unique among urologic cancers in that surgery (RPLND) can cure patients 
that have metastatic disease. Of CS I patients choosing primary RPLND, 70% will have no 
metastatic disease in their retroperitoneum, and are classified as pathologic stage I. Despite 
negative lymph nodes, 10% will relapse, and thus these patients still require follow-up. The 
remaining 30% with occult cancer identified in the lymph nodes are classified as pathologic 
stage II. For patients with pathologic stage II disease, surgery alone is curative in 
approximately 70%, and those 30% that relapse are cured with chemotherapy. Irrespective 
of pathologic stage, 99% patients who choose primary RPLND will ultimately be cured of 
their disease. (Donohue, Thornhill, Foster, Rowland, & Bihrle, 1993b) 
1.5.2 Clinical outcomes of primary RPLND – low volume pathologic stage II disease 
Management options for pathologic stage II disease include observation or adjuvant 
chemotherapy, as both have equal survival. This is based on a randomized trial of 
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pathologic stage II patients which compared adjuvant chemotherapy to close observation 
(with chemotherapy for recurrence). (Williams, et al., 1987) Analysis revealed no difference 
in survival (95%) between the two treatment arms at a median follow-up of 4 years. 
Outcomes for patients with low volume pathologic stage II disease who choose observation 
are well described in the literature. Pathologic stage II disease was identified in 112 of 464 
patients undergoing primary RPLND at Indiana for what was originally staged as clinical 
stage I disease, from 1965 to 1989. (Donohue, Thornhill, Foster, Rowland, & Bihrle, 1993c) 
Sixty-six percent of those patients with pathologic stage II disease were cured by RPLND 
alone. Memorial Sloan Kettering reported an 81% four-year progression free probability for 
pathologic stage II patients who did not receive adjuvant chemotherapy following a full, 
bilateral RPLND with less than a 2cm retroperitoneal mass. (Stephenson et al., 2005) Similar 
results were obtained in a series from Indiana University which included 118 RPLND 
patients with pathologic stage II disease, who did not receive adjuvant chemotherapy, and 
were followed for a minimum of 2 years. The 5 year disease free survival for this cohort was 
68%. ( S. D. Beck, Foster, Bihrle, Cheng, & Donohue, 2005; S. D. Beck et al., 2005) 
Thus, 70% of patients with pathologic stage II disease are cured with RPLND alone, and 
those 30% that do relapse remain curable with 3 courses of chemotherapy. An alternative 
approach in managing pathologic stage II disease is 2 courses of adjuvant chemotherapy. 
While this approach reduces recurrence rates to less than 2%, (Behnia, Foster, Einhorn, 
Donohue, & Nichols, 2000; Culine et al., 1996; Gerl, Clemm, Kohl, & al., 1994; Kennedy, 
Torkelson, & Fraley, 1994; Kondagunta et al., 2004; Vugrin, Whitmore, Herr, Sogani, & 
Golbey, 1982; Weissbach & Hartlapp, 1991; Williams et al., 1987) it subjects all patients to 
chemotherapy, including the 70% who were cured by surgery alone. (Donohue, Thornhill, 
Foster, Rowland, & Bihrle, 1993a, 1995a; Richie & Kantoff, 1991)  
Similar to risk stratification in CS I disease, efforts have been made to identify risk factors 
predictive of relapse for pathologic stage II disease after RPLND. Knowledge of such risk 
factors would allow “high risk” patients to receive adjuvant chemotherapy, and “low risk” 
patients to be observed. To date, no pathologic or clinical variable has been identified to 
predict relapse. (S. D. Beck, et al., 2007) (S. D. Beck, R. S. Foster, R. Bihrle, L. Cheng, & J. P. 
Donohue, 2005) (S. D. Beck, R. S. Foster, R. Bihrle, L. Cheng, T. M. Ulbright, et al., 2005) 
(Rabbani et al., 2001) (Richie & Kantoff, 1991)  
1.5.3 Primary RPLND technique 
The traditional full bilateral suprahilar RPLND involved removal of all lymphatic tissue 
from the suprahilar areas to the bifurcation of the common iliac arteries, from ureter to 
contralateral ureter. This was, by intent, a radical procedure, because chemotherapeutic 
rescue was not available when full bilateral RPLND was initially developed. All 
sympathetic efferent fibers were sacrificed, and lymphatic tissue was removed en bloc. 
Therefore, these patients suffered from anejaculation post-operatively. 
Since the original extent of dissection was developed, it has been discovered, through the 
advent of CT scanning, and with the aid of meticulous anatomic mapping studies, that 
patients with clinical stage I disease may be treated with a much more limited dissection in 
the retroperitoneum, ipsilateral to the affected testis. Specifically, patients with low-volume 
retroperitoneal tumor from a left sided primary characteristically had metastases localized 
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to the upper left periaortic zone, and patients with low-volume disease from a right-sided 
primary were found to have metastases to the interaortocaval or precaval zones. These facts 
led investigators to modify the traditional full bilateral RPLND further and limit the 
dissection to the left- and right-sided templates, as depicted in Figures 1 and 2.  
 
Fig. 1. Left-sided RPLND Template. Artist’s rendering of the retroperitoneum. Orange area 
depicts area of surgical dissection. 
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Fig. 2. Right-sided RPLND Template. Artist’s rendering of the retroperitoneum. Orange area 
depicts area of surgical dissection. 
With these templates, right and left sided dissection would remove lymphatic tissue at high 
risk of harboring metastatic disease, but preserve other retroperitoneal lymphatic tissue at low 
risk of containing metastasis. The advantages of limiting the dissection in patients with low 
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volume disease were shorter operative times, and shorter postoperative ileus. Additionally, 
and most importantly, these templates saved contralateral retroperitoneal efferent sympathetic 
fibers, thereby preserving emission and ejaculation in roughly 50% to 70% of patients. 
The most recent modification in technique for RPLND for low-stage disease is the nerve-
sparing dissection, in which efferent sympathetic fibers are prospectively identified and 
dissected, and modified lymphadenectomy is then performed. This advancement in 
technique preserves the staging and therapeutic aspect of RPLND, while additionally 
improving upon ejaculation preservation rates. In Figure 3, the right-sided post-synaptic 
sympathetic nerves are enveloped by vessel loops, and are seen exiting the sympathetic 
chain from underneath an anteriorly retracted inferior vena cava (IVC). 
 
Fig. 3. Nerve-Sparing RPLND Technique. A photograph of the retroperitoneum during 
RPLND. The post-synaptic sympathetic nerves are encircled by white vessel loops for better 
visualization. Following the course of these nerves proximally, they can be seen joining the 
right sympathetic chain, which travels parallel and posterior to the inferior vena cava. The 
inferior vena cava is retracted anteriorly with vein retractors, to allow better visualization of 
the sympathetic chain. 
A laparoscopic technique has been developed in an effort to further diminish primary 
RPLND’s already favorable morbidity profile. It remains unknown as to whether or not the 
laparoscopic technique offers a morbidity benefit compared to the open technique. (Abdel-
Aziz et al., 2006; Albqami & Janetschek, 2005; Janetschek, Hobisch, Holtl, & Bartsch, 1996; 
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Kenney & Tuerk, 2008) Furthermore, the vast majority of laparoscopic primary RPLND 
patients receive adjuvant chemotherapy following surgery, thus the therapeutic benefit of 
laparoscopic RPLND alone also remains unknown. (Rassweiler, Scheitlin, Heidenreich, 
Laguna, & Janetschek, 2008)  
1.5.4 Morbidity of primary RPLND 
Although primary RPLND as a treatment strategy offers excellent cure rates, it nonetheless 
subjects 70% of patients to unnecessary surgery. Fortunately, the morbidity of a primary 
RPLND is essentially that of a laparotomy. (Foster et al., 1994; Heidenreich et al., 2003; 
Jewett, 1990) A review of the experience at Indiana University showed that the only 
significant long-term morbidity is an approximate 1% chance of postoperative small bowel 
obstruction due to adhesions. (Baniel, Foster, Rowland, Bihrle, & Donohue, 1994) The same 
institution recently reviewed 75 consecutive primary retroperitoneal lymph node 
dissections. (S.D.W. Beck, Peterson, Foster, Bihrle, & Donohue, 2006) In this population the 
mean operative time was 132 minutes, mean blood loss was 207 cc. Nasogastric tubes are 
not routinely used in either primary or post chemotherapy surgery, and in this series only 2 
patients had NG tubes. The mean hospital stay was 2.8 days (range: 2-4). With nerve-sparing 
technique, 99% maintain antegrade ejaculation, and a 75% fertility rate is observed. (S. D. 
Beck, Bey, Bihrle, & Foster, 2010; Foster et al., 1994) (S. D. Beck, Bey, Bihrle, & Foster, 2010; 
Foster, et al., 1994) This compares favorably to fertility rates for surveillance, and is roughly 
equivalent to fertility rates seen with chemotherapy. 
1.5.5 Follow up for primary RPLND 
Irrespective of pathologic stage at primary RPLND, the risk of relapse in the retroperitoneum 
is exceedingly low, with most relapses identified by chest X-ray and/or serum tumor markers. 
As such abdominal imaging with CT scan is not routinely used and follow-up consists of 
periodic chest X-ray, serum tumor markers, and physical examination. Given the rarity of 
relapse more than 2 years after remission, especially in the RPLND population, (Baniel et al., 
1995) further follow-up accordingly becomes less rigorous in subsequent years. 
1.5.6 Summary: Primary RPLND for clinical stage I disease 
Though RPLND subjects all patients to a laparotomy (including the 70% that were 
pathologic stage I and did not require surgery), with nerve-sparing technique antegrade 
emission is preserved, and long term morbidity includes an abdominal scar and a 1% chance 
of latent small bowel obstruction. RPLND offers unique advantages over observation or 
adjuvant chemotherapy, including immediate pathologic staging, a simplified and less 
anxiety-prone follow-up involving less radiation exposure, and the potential for cure and 
the avoidance of chemotherapy for pathologic stage II patients.  
1.6 Special considerations in stage I disease 
1.6.1 Clinical stage I s patients 
A small percentage of patients have elevated serum tumor markers which do not normalize 
appropriately following radical orchiectomy, despite an otherwise normal metastatic work-
up, and are defined as clinical Stage I s disease. By virtue of the increased markers, these 
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patients continue to harbor disease. While some have advocated RPLND in such situations, 
confinement of disease to the retroperitoneum is not assured, thus additional chemotherapy 
may be necessary should RPLND not affect cure. As a result, chemotherapy is 
recommended for Stage Is patients. 
1.6.2 Chemoresistant pathology  
A small subset of patients have adenocarcinoma, teratoma with malignant transformation 
(such as primitive neuroectodermal tumour (PNET)), or a sex chord stromal tumor in their 
orchiectomy specimen. These histologies are chemoresistant, and a subsequent relapse is 
unlikely to be responsive to chemotherapy. Thus, first line treatment should be RPLND.  
1.7 Summary: Management options for clinical stage I non-seminomatous germ cell 
tumor of the testis 
Appropriate treatment of Stage I NSGCT requires knowledge of the risk factors associated 
with recurrence, foresight regarding the likely outcomes and percentages associated with 
the three treatment strategies, the morbidities unique to each modality, and most 
importantly a keen understanding of a patient’s desired approach to this complicated 
problem. Given that all three treatment modalities offer equivalent cure rates, a treatment 
strategy which focuses on minimizing overall morbidity, and approaches the problem in a 
manner which is synergistic with a patient’s wishes, is most likely to be successful. 
2. Management options for clinical stage II and III non-seminomatous germ 
cell tumor of the testis 
Patients with clinical stage II disease have evidence of disease confined to their 
retroperitoneum following radical orchiectomy. Clinical stage III patients have disease 
outside of the retroperitoneum following orchiectomy. Patients with small volume (<5cm) 
stage II disease and normal serum tumor markers post-orchiectomy may be treated with 
either primary RPLND or induction chemotherapy. Patients with “bulky” stage II disease, 
those with persistently elevated serum tumor markers, and all patients with clinical stage III 
disease, require cisplatinum-based chemotherapy. 
2.1 Primary RPLND for low volume clinical stage II disease 
2.1.1 Clinical outcomes of primary RPLND 
As with clinical stage I disease, primary RPLND in low volume clinical stage II disease is 
both a staging and a therapeutic procedure. Following RPLND, further treatment decisions 
are based upon the pathologic stage of disease, regardless of the initial clinical stage at 
presentation. Donohue reported on 174 clinical stage II patients undergoing full, bilateral 
primary RPLND from 1965 to 1989. (Donohue, Thornhill, Foster, Rowland, & Bihrle, 1995b) 
Interestingly, 23% of patients originally staged as CS II disease were shown to be pathologic 
stage I disease following primary RPLND. 65% of those patients who were pathologic stage 
II with a nodal mass of less than 5 cm were cured by RPLND alone – that is, did not receive 
adjuvant chemotherapy. Thus patients with clinical stage II disease who are proven to be 
pathologic stage II are cured at roughly the 70% level with surgery alone.  
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2.2 Induction chemotherapy for clinical stage II and III disease 
2.2.1 Clinical outcomes of induction chemotherapy 
All patients with persistently elevated tumor markers post orchiectomy and CS III 
patients should initially be treated with induction chemotherapy. Chemotherapy for germ 
cell tumors is cisplatinum-based, and the specific regimen is dictated by risk classification, 
using the International Germ Cell Cancer Consensus (IGCCC) classification system, which 
assigns risk based on the site of the primary tumor, post-orchiectomy serum tumor 
markers, and the site(s) of metastatic disease (Table 2). ("International Germ Cell 
Consensus Classification: a prognostic factor-based staging system for metastatic germ 
cell cancers. International Germ Cell Cancer Collaborative Group," 1997) Good risk 
patients are treated with 3 courses of bleomycin, etoposide, and cisplatinum (BEP). 
(Culine et al., 2007; Einhorn et al., 1989) In good risk patients over age 50 or with a strong 
smoking history, bleomycin may be omitted and 4 cycles of EP may be given instead. 
(Bosl et al., 1988; Culine, et al., 2007; Xiao et al., 1997) Standard therapy for intermediate 
and poor risk patients is 4 courses of BEP. Randomized trials evaluating high dose 
chemotherapy (HDCT) versus 4 cycles of BEP in poor risk patients as initial therapy failed 
to show an improved outcome in the HDCT arm. (Motzer et al., 2007) Overall, depending 
upon the patient population selected, roughly 70% of patients treated with induction 
chemotherapy for CS II or III disease will obtain a complete clinical response (CR) with 
normalization of serum tumor markers and complete radiographic resolution of all 
metastatic disease.  
 Good Prognosis Intermediate Prognosis Poor Prognosis 
Primary Site Testis or Retroperitoneal Testis or Retroperitoneal Mediastinal  
Metastases 
Site 
No nonpulmonary 
visceral  
No nonpulmonary 
visceral  
Nonpulmonary visceral  
Post 
Orchiectomy 
Serum Tumor 
Markers 
AFP<1000 ng/mL 
βhCG<5000 IU/L 
LDH<1.5 x Normal 
upper limit 
AFP 1-10,000 ng/mL 
βhcG 5-50,000IU/L 
LDH 1.5-10 x Normal 
upper limit 
AFP>10,000 ng/mL 
βhCG>50,000 IU/L 
LDH>10 x Normal 
upper limit 
Table 2. International Germ Cell Consensus Classification of Non Seminoma 
2.3.1 Post-chemotherapy RPLND following complete response to induction 
chemotherapy 
Following induction chemotherapy for CS II or III disease, patients achieving a CR are 
observed, as the risk of relapse is approximately 5%. (Ehrlich, Brames, Beck, Foster, & 
Einhorn, 2010) Recently, it has been shown that 20-25% of CR patients undergoing PC 
RPLND harbour microscopic teratoma in their retroperitoneum. (Karellas et al., 2007; 
Oldenburg et al., 2003) Thus there has emerged a controversy due to the disconnect between 
the pathologic finding of microscopic teratoma (20-25%) and clinically observed relapse 
rates (5%). The concern for physicians advocating immediate PC RPLND in this population 
is that with longer follow-up, the relapse rate will approach 20-25%. However, at 15 year 
follow-up, the relapse rate remains roughly 5%, thus the data continues to support 
surveillance as an appropriate strategy for CR patients. 
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2.3.2 PC RPLND for residual mass following induction chemotherapy 
It is accepted worldwide that patients with normalization of serum tumor markers and 
persistent retroperitoneal mass following chemotherapy undergo PC RPLND. In this 
population, pathology reveals necrosis in 45%, teratoma in 45%, and active cancer in 10% 
(Toner et al., 1990).  
For patients with necrosis at PC RPLND, surgery is a staging procedure only, and offers no 
therapeutic benefit. Relapse rates are approximately 5%, and no additional chemotherapy is 
required.  
For patients with teratoma at PC RPLND, adjuvant chemotherapy is not given, as teratoma 
is chemotherapy insensitive. Nonetheless, teratoma at PC RPLND requires careful follow-
up, as recurrence rates are not insignificant, and range from 5-20% with increasing size of 
mass. With a median post chemotherapy mass size of 3.0 cm, Memorial Sloan Kettering 
reported disease free survival of 83% at 5-years for resected teratoma. (Carver et al., 2007) In 
this study, patients with residual mass size less than 2 cm, 2 to 5 cm and > 5 cm had 5-year 
probabilities of freedom from recurrence of 94%, 91% and 59%, respectively (p < 0.0005). 
Other authors have had similar results. (Carver, et al., 2007; Loehrer et al., 1986; Svatek et al., 
2009) Investigators from Indiana University recently reported recurrence rates after 
resection of large volume (> 10 cm) teratoma. (S. D.W. Beck, Foster, Bihrle, Donohue, & 
Einhorn, 2007) The 2 and 5-year recurrence free survival for the 99 patients was 86% and 
75%, with a mean follow up of 42 months, suggesting that in large volume masses, 
recurrence rates are also noteworthy. As a result, follow-up of teratoma at PC RPLND need 
include serial abdominal CT scan.  
The presence of active cancer at PC RPLND portends a poor prognosis, and it has been 
standard practice to give two courses of adjuvant chemotherapy. In this population, Spiess 
reported the 5 year disease-free survival rate to be 50%. (Spiess et al., 2007) An international 
study group on testis cancer reported the outcomes of 238 patients with active cancer at PC 
RPLND. Variables predictive of survival included incomplete surgery, viable malignant 
cells > 10% of surgical specimen, and poor or intermediate IGCCC risk category. (Fizazi et 
al., 2001)Patients with no adverse factors experienced a 5-year progression free survival of 
90% compared to 41% for 2 or more risk factors. Furthermore, on multivariate analysis 
postoperative chemotherapy was associated with a significantly better progression free 
survival (p < 0.001), but not overall survival (p = 0.26). Thus, while adjuvant chemotherapy 
does not improve overall survival, it does reduce recurrence rates to 30%, and thereby 
avoids the morbidity of second line chemotherapy for those who do not recur.  
2.3.3 Follow-up after PC RPLND  
PC RPLND follow-up is based upon retroperitoneal pathology. Patients with necrosis are at 
low risk of relapse, and follow-up should include physical exam, serial chest imaging and 
serum tumor markers. Routine abdominal imaging is not necessary in this population. In 
addition to the routine follow-up necessary for necrosis, patients with teratoma are at some 
risk of retroperitoneal relapse, and therefore require serial abdominal CT scans. Follow-up 
for active cancer should be tailored individually, though will include physical exam, serum 
tumor markers, chest X-ray and abdominal imaging.  
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2.3.4 Summary: Induction chemotherapy and PC RPLND 
Following induction chemotherapy for clinical stage II or III disease, patients with a 
complete response to chemotherapy are most commonly managed with observation. 
Patients with a persistent retroperitoneal mass and negative serum tumor markers routinely 
undergo PC RPLND. 45% of PC RPLND patients will harbor necrosis, with a relapse rate of 
5%. 45% harbor teratoma with relapses ranging from 5-20%, depending on mass size. The 
10% of patients with active cancer in their retroperitoneum at PC RPLND are treated with 
adjuvant chemotherapy to improve disease-free survival. Adjuvant chemotherapy has yet to 
demonstrate improved overall survival in this population. 
2.4 Special considerations in stage II and III disease 
2.4.1 Induction chemotherapy failure 
Patients with disease relapse or disease progression despite first line chemotherapy are 
candidates for salvage therapy. Disease progression may be identified by persistently 
elevated tumor markers or increasing mass size. A minority of such patients will have 
anatomically confined disease that is amenable to surgical resection, and may undergo 
“desperation surgery”. (S. D. Beck, Foster, Bihrle, Einhorn, & Donohue, 2005; Murphy et al., 
1993) For the remaining patients with multifocal disease, treatment options include salvage 
chemotherapy with cisplatin plus ifosfamide plus vinblastine, (Loehrer, Gonin, Nichols, 
Weathers, & Einhorn, 1998) or paclitaxel (Motzer, Sheinfeld, et al., 2000) for four courses, or 
high-dose chemotherapy with autologous hematopoietic stem-cell transplantation to rescue 
the bone marrow from the myeloablative effect of chemotherapy. (Einhorn et al., 2007; 
Motzer, Mazumdar, et al., 2000; Rick et al., 1998) 
2.4.2 Determining the extent of dissection at PC RPLND  
Many patients from the 1970’s and 1980’s undergoing post chemotherapy surgery had high 
volume residual disease and the decision to perform a full, bilateral RPLND was therefore 
rational and appropriate. Since chemotherapy is now being administered for relatively low 
volume retroperitoneal disease, and since these tumors are typically restricted to the 
primary landing zone of the affected testicle, the question has arisen as to the 
appropriateness of full bilateral PC RPLND in this population.  
Proponents of modified dissections note that with appropriate patient selection, the risk of 
extra-template disease and its clinical significance is low. In 1992, investigators from 
Memorial Sloan-Kettering published a series of 113 patients undergoing full bilateral PC 
RPLND, with an 8% incidence of disease (cancer/teratoma) identified in the contralateral 
landing zone. (D. P. Wood, Jr., Herr, Heller, et al., 1992) This cohort all presented with 
“bulky disease”, and were treated with cisplatin- or carboplatin-based chemotherapy. Based 
upon these findings, the authors concluded that a modified dissection should be considered 
in patients with 1) no palpable residual tumor mass, 2) a left primary tumor, or 3) a right 
primary tumor and no evidence of cancer/teratoma on frozen section analysis of the 
residual mass. Fossa et al. reported the results of 87 patients with residual masses less than 
20 mm undergoing modified PC RPLND. (Oldenburg, et al., 2003) Pathology revealed 
necrosis in 67%, teratoma in 26%, and cancer in 7%. Five relapses occurred in this study, 
with no recurrences in the retroperitoneum, indicating that the template of dissection was  
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adequate. Indiana University recently reported outcomes of 100 patients undergoing a 
modified post chemotherapy dissection. (S.D.W. Beck, Foster, Bihrle, & Donohue, 2005) The 
selection criteria included low-volume retroperitoneal disease (< 5 cm) both pre- and 
postchemotherapy, restricted to the primary landing zone of the affected testicle. Pathology 
revealed cancer in 2%, teratoma in 62% and necrosis in 36%. Three patients relapsed, all 
outside the boundaries of a full bilateral dissection, and the 2-year progression free survival 
was 95%. Others have also demonstrated the safety of a modified PC RPLND in select 
patients, (Ehrlich, Yossepowitch, Kedar, & Baniel, 2006; Rabbani et al., 1998) thus it appears 
that a modified dissection may be appropriate in select patients. 
Though limited dissection is appropriate in a subset of patients, the vast majority of patients 
undergoing PC RPLND require a full, bilateral dissection. 
2.4.3 Complicated PC RPLND 
Complicated PC RPLND is defined as: 1) PC RPLND after more than induction 
chemotherapy (“salvage RPLND”), PC RPLND after previous RPLND (“redo RPLND”), or 
PC RPLND in the setting of persistently elevated markers or progression of disease after 
chemotherapy (“desperation RPLND”). (Donohue, et al., 1998) 
Indiana University reported the outcomes of patients undergoing “complicated” RPLND. 
The incidence of active cancer at “salvage” RPLND was 50%, with an overall survival of 
50% to 60%. There appeared to be no benefit with adjuvant chemotherapy in this 
population. Overall survival for the 188 patients undergoing “redo” surgery was 63%. 
Memorial Sloan-Kettering reported a 67% 5-year disease specific survival for 57 patients 
undergoing redo surgery. (McKiernan et al., 2003) Historically, persistent serum tumor 
marker elevation after chemotherapy has been considered a relative contraindication to 
surgery, due to supposed systemic disease and low chance of cure with local therapy alone. 
These “desperation” patients were therefore treated with salvage chemotherapy. Over the 
last 15 years, however, several centers have experienced surgical cures in this population. (S. 
D. Beck, R. S. Foster, R. Bihrle, L. H. Einhorn, et al., 2005; Eastham, Wilson, Russell, 
Ahlering, & Skinner, 1994; Murphy, et al., 1993; D. P. Wood, Jr., Herr, Motzer, et al., 1992) 
Thus, a subset of patients with elevated serum tumor markers after chemotherapy are 
curable with surgery. Approximately 50% of patients undergoing post chemotherapy 
surgery with elevated serum tumor markers are alive at 5-years. Half of these patients are 
found to harbor viable non-teratomatous germ cell tumor, and a third of these are alive at 5-
years. Interestingly, this small subset population observes no benefit from adjuvant 
chemotherapy. Clearly, there is a role for surgery in selected patients with elevated serum 
tumor markers. The decision to proceed with surgery in lieu of second or third line 
chemotherapy involves identifying patients that are unlikely to obtain a complete response 
with systemic therapy, are of acceptable surgical candidacy, are harboring resectable tumors 
which could potentially be curable with negative margins, and following resection are 
offered acceptable morbidity profiles.  
2.4.4 Surgical management of pulmonary extraperitoneal disease 
Selection of patients for pulmonary resection typically includes patients with residual lung 
nodules and normal serum tumor markers after chemotherapy. Much like PC RPLND, 
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resection of residual teratoma or active cancer in the pulmonary system can be therapeutic 
and therefore the morbidity of thoracotomy is justified. Conversely, resection of residual 
necrosis is a staging procedure only.  
Efforts to predict pulmonary histology prior to surgical resection have been somewhat 
successful. Excluding series with less than 100 patients, there are 2 retrospective studies 
identifying variables predictive of pulmonary histology. Tognini et al reviewed 143 post 
chemotherapy patients who underwent resection of residual retroperitoneal and chest disease 
under the same anesthetic. (Tognoni et al., 1998) Pathologic concordance between pulmonary 
and retroperitoneal masses existed in 77.5% of patients with necrosis, 70% with teratoma, and 
69% with active cancer. For surgery-naïve patients experiencing normalization of tumor 
markers following first line chemotherapy, a pathologic concordance between pulmonary and 
retroperitoneal masses of 86% for patients with necrosis was seen. An international, 
multicenter, retrospective review evaluated the concordance of retroperitoneal and pulmonary 
histology in 215 patients. (Steyerberg et al., 1997) The strongest predictor of pulmonary 
histology was the histology found at PC RPLND -- if PC RPLND histology revealed necrosis, 
the probability of necrosis at thoracotomy was 89%.  
As such, patients with small pulmonary nodules may be observed with serial chest imaging. 
Masses which enlarge on observation are thus identified, and represent the small proportion 
of patients with residual disease in the form of teratoma (5%) or active cancer (1-4%). Such 
patients could conceivably then undergo surgical resection without a decrease in their 
expected survival rate. In fact, in subgroups with pulmonary nodules and necrosis in the 
retroperitoneum, such an approach would spare more than 90% of patients the morbidity of 
thoracotomy.  
There is no data comparing immediate resection of residual pulmonary nodules versus 
delayed resection upon progression. Decision-making with regard to residual pulmonary 
mass resection must take into account technical feasibility, patient morbidity and potential 
benefit, future access to health care, and of course patient preference. 
2.4.5 Surgical management of nonpulmonary extraperitoneal disease 
NSGCT metastatic to extraperitoneal sites beyond the pulmonary system are quite rare, and 
require specific site-based therapeutic approaches.  
Residual post-chemotherapy mediastinal or neck masses are typically removed either at 
time of RPLND or as a staged procedure.  
Brain metastases occur in 1% of patients, and Cisplatin-based chemotherapy is 
recommended as initial therapy in patients with brain metastases at initial presentation. 
Balmaceda et al reported a 57% complete response rate in 68 patients with brain 
involvement with chemotherapy alone. (Balmaceda et al., 1996) Surgical resection should be 
considered for residual disease. Radiotherapy does not appear to influence survival in this 
select population, and confers considerable morbidity by way of declining functional 
cognitive status. 
Indiana University demonstrated that approximately 70% of resected liver lesions are 
necrosis and the histologic concordance between retroperitoneal histology and liver 
histology is 94.4% for necrosis, 25.9% for teratoma and 38.5% for active cancer. (Jacobsen et 
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al.) With this data in mind, observation of liver metastases should be considered when 
retroperitoneal histology reveals necrosis or when the volume and/or location of the hepatic 
involvement require a significant surgical undertaking. If the mass enlarges on surveillance, 
then surgery or second-line chemotherapy should be considered.  
2.4.6 Management of late relapse  
Late relapse of testis cancer is defined as recurrence of disease later than 2 years after initial 
successful treatment. In a pooled analysis of 5880 patients, late relapse occurred in 119 of 
3704 (3.2%) patients with non-seminoma. The retroperitoneum is the predominant site of 
relapse, followed by the lung, and 70% present with an elevated AFP. About 40% to 50% of 
patients with late relapse are curable, predominantly through surgery, as these tumors are 
by and large chemoresistant. (Baniel, et al., 1995; George et al., 2003)  
2.5 Summary: Management options for clinical stage II and III non-seminomatous 
germ cell tumor of the testis 
Patients with low-volume clinical stage II disease with normal serum tumor markers may 
undergo primary RPLND in lieu of systemic chemotherapy. Surgery alone without 
chemotherapy can cure 50-70% of patients with pathologic stage II disease. The remainder 
are cured with chemotherapy at relapse.  
Patients with elevated serum tumor markers, bulky clinical stage II disease, and all clinical 
stage III patients require induction chemotherapy. 70% of these patients will achieve CR, 
and these patients are observed, as the relapse rate is less than 5%. Patients with 
normalization of serum tumor markers and a persistent retroperitoneal mass routinely 
require PC RPLND. Outcome is dependent upon pathology. 
Patients with more complicated disease require individualized therapy, which may involve 
salvage chemotherapy, surgery, or both. Relapses occurring more than two years since last 
treatment are best approached with surgery. Patients requiring “complicated” PC RPLND, 
presenting with late relapse, or harboring extraperitoneal disease are candidates for referral 
to tertiary centers of considerable experience in these difficult scenarios. 
3. Explanation of terms and abbreviations 
Adjuvant Chemotherapy – A term denoting chemotherapy that is administered after first 
receiving definitive local therapy (such as surgery). This second therapy is given to patients 
under the assumption that micrometastatic disease persists despite the initial local therapy.  
CT A & P – Computed Tomography Scan of the Abdomen and Pelvis. Providing detailed 
information about the size and location of potential sites of metastatic testis cancer in the 
abdomen and pelvis, these scans are the pelvic imaging modality of choice for surveillance 
and investigation of nonseminomatous germs cell tumors. 
CXR – Chest X-ray. A chest imaging modality for the surveillance and investigation of 
patients with nonseminomatous germ cell tumors of the testis. 
Induction Chemotherapy – A term denoting chemotherapy that is administered as initial 
treatment where disease is too advanced for other modalities (such as surgery). 
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IVC – Inferior Vena Cava. Anatomical term for large vein coursing through 
retroperitoneum, returning venous blood to the right atrium. Metastatic testis cancer 
frequently intimately involved with this structure. 
PC RPLND – Post-chemotherapy retroperitoneal lymph node dissection. Surgical procedure 
to remove all lymphatic tissue in the retroperitoneal space which lies between the ureters, 
superior to the common iliac vessels, and inferior to the crus of the diaphragm, performed 
after patient has received chemotherapy.  
RPLND – Retroperitoneal lymph node dissection. Surgical procedure to remove all 
lymphatic tissue in the retroperitoneal space which lies between the ureters, superior to the 
common iliac vessels, and inferior to the crus of the diaphragm. 
Salvage Chemotherapy – A term denoting chemotherapy given after relapse or progression of 
disease, despite prior induction chemotherapy  
STM – Serum tumor markers. In nonseminomatous germ cell tumor of the testis, the most 
important markers are alpha fetoprotein (AFP), the beta subunit of human chorionic 
gonadotropin (βhCG) and lactate dehydrogenase (LDH). These proteins are easily isolated 
from blood samples, and are highly reliable in terms of their ability to quantify disease 
burden and/or assess response to therapy. 
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